Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Beijing Xiaotangshan Hospital | OTHER |
| The First Hospital of Fangshan District,Beijing | OTHER |
| Beijing Ditan Hospital | OTHER |
| Hengshui People's Hospital |
Not provided
Not provided
Not provided
Not provided
This trial's primary objective is to compare the analgesic efficacy of esketamine in combination with pulsed radiofrequency (PRF) against that of PRF monotherapy in patients with trigeminal postherpetic neuralgia (TPHN).
This study aims to determine whether the addition of esketamine to the PRF regimen can relieve pain in TPHN patients. By doing so, the research endeavors to identify a rapid, effective, and safe treatment approach for refractory TPHN patients
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| esketamine group | Experimental | In addition to receiving PRF treatment+pregabalin, patients will also undergo a single intravenous infusion of esketamine |
|
| control group | Placebo Comparator | patients will receive PRF treatment+pregabalin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| esketamine group | Drug | In the esketamine group, in addition to receiving PRF treatment+pregabalin for rescue analgesia, patients will also undergo a single intravenous infusion of esketamine. A total of 0.5 mg/kg of esketamine will be diluted in 50 mL of normal saline. The infusion will commence with an intravenous injection of 10 mg of esketamine over 1 minute, followed by a maintenance dose of 8 mg/h. The infusion rate will be adjusted based on the patients' tolerance levels. |
| Measure | Description | Time Frame |
|---|---|---|
| 1.the difference between the means of the daily mean pain scores over the first 7 days, measured on an 11-point Numeric Rating Scale（NRS） | NRS score is a way to quantify the degree of subjective feelings such as pain using numbers. Generally, 0 represents no pain, and 10 represents the most severe pain.A higher score indicates more severe pain | 7-day period |
| Measure | Description | Time Frame |
|---|---|---|
| average weekly NRS score | average weekly NRS score of each participants for rescue analgesia.NRS score is a way to quantify the degree of subjective feelings such as pain using numbers. Generally, 0 represents no pain, and 10 represents the most severe pain.A higher score indicates more severe pain | up to 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Fang Luo, M.D. | Contact | +86 13611326978 | 13611326978@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing Tiantan Hospital | Beijing | Beijing Municipality | 100070 | China |
Not yet decided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009437 | Neuralgia |
| ID | Term |
|---|---|
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D010146 | Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
|
|
| control group | Drug | In the control group, patients will receive PRF+pregabaline treatment. Pulsed radiofrequency (PRF) will be performed on GG by a designated physician in each participating center. PRF treatment (PMG-230, Baylis Medical Inc.) targeting to GG will be applied for 900 seconds. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. Regarding pregabalin, the dosage is titrated based on patients'pain intensity and tolerance. This process fully accounts for individual patient differences to optimize treatment outcomes. |
|
|
| averaged weekly analgesic consumption |
averaged weekly consumption per analgesic of each participant |
| up to 12 weeks |
| the 12-item Short-Form Health Survey (SF-12) score | Quality of life (QoL) assessed by the SF-12 score(range 0-100, with higher scores indicating better health status) | At the end of weeks 1, 2, 4, 8, and 12 after treatment |
| the Pittsburgh Sleep Quality Index (PSQI) score | Sleep quality measured by PSQI score(range 0-21, with higher scores indicating poorer sleep quality) | At the end of weeks 1, 2, 4, 8, and 12 after treatment |
| the Patient Global Impression of Change scale (PGIC) | The Patient Global Impression of Change (PGIC) is usually a 7 - point scale. The scale title is "Patient Global Impression of Change". The minimum value is 1 and the maximum value is 7.In summary, for the PGIC scale, lower scores (from 1 to 3) mean a better outcome, indicating improvement in the patient's condition, while higher scores (from 5 to 7) mean a worse outcome, suggesting a deterioration of the condition. Score 4 represents a neutral state of no change. | At the end of weeks 1, 2, 4, 8, and 12 after treatment |
| the Hospital Anxiety and Depression Scale (HADS) | It 6.consists of two sub-scales. Each sub-scale consists of 7 items and each item scored from 0 to 3. A higher score indicates more severe anxiety or depression. A score of 11 or above can indicate clinically significant anxiety or depression. | At the end of weeks 1, 2, 4, 8, and 12 after treatment |
| Safety assessments | intraoperative complications, PRF-related complications, Eskatamine-related complications, Pregabaline-related complications | Conducted on Day 0, Day 1, Day 3, and at the end of weeks 1, 2, 4, 8, and 12 after treatment |
| D009461 |
| Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D008722 | Methods |